Last reviewed · How we verify
HG004
At a glance
| Generic name | HG004 |
|---|---|
| Sponsor | HuidaGene Therapeutics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR) (PHASE1, PHASE2)
- Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HG004 CI brief — competitive landscape report
- HG004 updates RSS · CI watch RSS
- HuidaGene Therapeutics Co., Ltd. portfolio CI